trending Market Intelligence /marketintelligence/en/news-insights/trending/a3xkhj0MeWqbNtVJiP6VOQ2 content esgSubNav
In This List

Lupin launches generic female contraceptive in US

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Lupin launches generic female contraceptive in US

Lupin Ltd. launched a generic version of Janssen Pharmaceuticals Inc.'s female contraceptive tablet Ortho-Cyclen.

The norgestimate and ethinyl estradiol tablets are approved by the U.S. FDA. Ortho-Cyclen generated $204 million in U.S. sales during the 12 months ended September 2016, according to IMS Health data.

Janssen Pharmaceuticals is a Johnson & Johnson unit.